Department of Cardiology, St. Antonius Hospital, Koekoekslaan 1, 3435CM, Nieuwegein, The Netherlands.
Department of Cardiology, Amsterdam University Medical Centres, location Academic Medical Centre, Amsterdam, The Netherlands.
J Interv Card Electrophysiol. 2021 Mar;60(2):261-270. doi: 10.1007/s10840-020-00728-8. Epub 2020 Apr 6.
The second-generation multi-electrode catheter, pulmonary vein ablation catheter (PVAC) GOLD, was designed to improve the delivery of phased radiofrequency energy and reduce procedure times using a 'single-shot' approach for pulmonary vein isolation (PVI), while retaining efficacy and safety. This large registry presents acute success rates and safety outcomes in a daily practice setting.
A total of 1017 patients undergoing first-time ablation for atrial fibrillation (AF) using PVAC GOLD were included, 644 patients with paroxysmal AF and 373 patients with non-paroxysmal AF, divided into 175 patients receiving PVI only and 198 patients receiving PVI with additional substrate modification.
High and comparable percentages of successful PVI could be achieved in all groups (98%, 95% and 99%; p = 0.108). The median total procedure time for all groups was 90 min [70-100]. As expected, the total procedure, ablation and fluoroscopy time were significantly longer in the PVI + substrate modification group compared with the PVI-only cases (all p < 0.001), but not between the PVI-only groups (p = 0.306, p = 0.088, p = 0.233, respectively). A total of 44 complications were observed in 43 patients (4.2%). Major complications were seen in 19 patients (1.87%) and non-major procedure-related complications were seen in 25 patients (2.46%). Complications leaving permanent sequelae were rare and occurred in only four patients (0.39%). Complications did not differ between groups (p = 0.199, p = 0.438, p = 0.240 and p = 0.465 respectively).
PVAC GOLD performs successful PVI, while reducing procedure times and retaining safety for paroxysmal, persistent and long-standing persistent AF. Safety was unaffected by additional substrate modification.
第二代多电极导管,肺静脉消融导管(PVAC)GOLD,旨在通过“单次”方法改善相控射频能量的传递并减少程序时间,从而实现肺静脉隔离(PVI),同时保持疗效和安全性。这项大型注册研究在日常实践环境中呈现了急性成功率和安全性结果。
共纳入 1017 例首次使用 PVAC GOLD 行消融术治疗心房颤动(AF)的患者,644 例阵发性 AF 和 373 例非阵发性 AF,分为仅行 PVI 的 175 例患者和行 PVI 加附加底物修饰的 198 例患者。
所有组均能达到高且可比的成功 PVI 百分比(98%、95%和 99%;p=0.108)。所有组的中位总手术时间为 90 分钟[70-100]。正如预期的那样,与仅行 PVI 组相比,PVI+底物修饰组的总手术、消融和透视时间明显更长(所有 p<0.001),但仅行 PVI 组之间没有差异(p=0.306、p=0.088、p=0.233)。43 例患者(4.2%)共观察到 44 种并发症。19 例患者(1.87%)出现严重并发症,25 例患者(2.46%)出现非严重手术相关并发症。仅有 4 例患者(0.39%)出现永久性后遗症并发症。并发症在各组之间无差异(p=0.199、p=0.438、p=0.240 和 p=0.465)。
PVAC GOLD 可成功行 PVI,同时减少手术时间并保持阵发性、持续性和持久性 AF 的安全性。安全性不受附加底物修饰的影响。